SFRP4 and tuberous sclerosis: Compared with the model group, the mRNA and protein expression levels of β-catenin, c-Myc, and cyclin D1 were significantly reduced after TSC drug intervention, whereas the mRNA and protein expression levels of the negative regulatory protein SFRP4 of the Wnt pathway were significantly increased.